• Article highlight
  • Article tables
  • Article images

Article Metrics




Downlaod Files

   


Article Access statistics

Viewed: 1204

PDF Downloaded: 753


Get Permission Patil, Sonawane, Khan, and Patil: Forced degradation study of different brands of levocetirizine dihydrochloride by UV-spectroscopy


Introduction

Levocetirizine dihydrochloride (LCT), (-)-cetirizine dihydrochloride; 2-[2-[4-[(R)-(4-chlorophenyl)-phenyl-methyl]piperazin-1-yl]ethoxy]acetic acid dihydrochloride, (Figure 1) is a third generation non sedative antihistamine, H1-receptar antagonist and is the active enantiomer of cetirizinedihydrochloride.1, 2, 3, 4 It is used to treat seasonal or perennial allergic rhinitis and chronic idiopathic urticarial.5, 6, 7

Figure 1

Chemical structure of Levocetirizine dihydrochloride

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/170d0a80-30f9-44b8-b067-80f142ec8632/image/22829d4b-bfe6-4be9-ba9a-6cbe9cf47709-uimage.png

Analysis is an essential component in the formation of any drug molecule in formulation. Development of a simple, sensitive, accurate, precise and reproducible method for estimating the drug sample becomes important.8

In previous studies, the UV spectrophotometric method was developed and validated in accordance with the guidelines of the International Conference on Harmonization (ICH).[4] Generally speaking, spectrophotometry is preferred, particularly by small industries as the equipment cost is less and the maintenance is minimal. The analytical approach is based on measuring the absorption of a monochromatic light by colourless compound in spectral near-ultraviolet region (200-380 nm).9 UV spectrophotometry may be used to test LCT and its degraded products for stress degradation. According to ICH guidelines, the active pharmaceutical ingredient is subject to a range of forced degradation conditions, including acidic, basic, hot liquid, photolytic and oxidative conditions.10

Force degradation should be one of the early development activities to ensure that the method is discriminatory before a lot of time, effort, and money has been increased. Defining the conditions responsible for degrading the drug is essential.8

Earlier publications had described stability indicating liquid chromatography tandem mass spectrometric (LC-MS/MS).11 liquid chromatography (LC),12 reverse phase high performance liquid chromatography (RP-HPLC),7 methods for quantification of LCT in human plasma and pharmaceutical dosage form. However, these methods involve difficult sample preparation and long chromatographic run time with an organic phase and different buffer proportions. In addition, it is even more difficult and time-consuming to determine the stress-degraded behaviour of LCT. Hence, the main aim of this work is to study LCT’s stability behaviour using simple UV-spectrophotometric method.

Materials and Methods

Chemicals and reagents

API of LCT pure drug was obtained from Emcure Pharmaceuticals Ltd., Pune, India, as a gift sample with 99.38% (w/w) assay value. Levocetirizine dihydrochloride brands used were Okacet-L 5 mg tablets of Cipla Ltd., LECOPE 5 mg tablets of Mankind Pharma Ltd., Levocet 5 mg tablets of Hetero Healthcare Limited, 1-AL 5 mg tablets of FDC Limited. All chemicals and reagents used were of analytical grade.

Instrumentation

The instruments uses was Double-beam UV/Visible spectrophotometer (Shimadzu 1800) consisting quartz cell with 1 cm path length loaded with UV-Probe software (Ver. 2.50), Analytical balance (Radwag AS 220/X), UV Cabinet (Lablink Instruments), Ultra-sonicator (Labman), Hot Air Oven (Aadarsh Technologies), Water Bath (Labline).

UV-Spectrophotometric method of LCT dihydrochloride.

As with previous research,4 the UV spectrophotometric method of levocetirizine dihydrochloride developed and validated. This method was used to study the LCT dihydrochloride stress degraded behaviour.

Preparing asolution

Phosphate buffer pH 7.0

Mix. of 0.50 gm of di-sodium hydrogen phosphate anhydrous and 0.301 gm of Potassium dihydrogen orthophosphate in 1000 ml water.

Diluent

The pH 7.0 phosphate buffer is used as the diluent.

Preparing a standard stock solution

Weight exactly 10 mg of LCT dihydrochloride in a 100 ml volumetric flask. Place in 70 ml of diluent, dissolve and dilute to volume with diluent to obtain a stock solution of 100 μg / ml.

Preparing a calibration curve

Aliquots of 0.5-2.5 ml of the stock solution portion were transferred to a series of 10 ml volumetric flasks and the volume was added to the diluent mark. In the range of 200-400 nm, the solution was scanned against blank. The average absorption value was found to be 230.60 nm versus blank. The calibration curve is plotted in the Figure 2, Figure 3.

Figure 2

Linearity UV scan of Levocetirizine dihydrochloride

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/170d0a80-30f9-44b8-b067-80f142ec8632/image/7e1d6f51-c8d1-46ea-8f77-163e101f64fd-uimage.png

Figure 3

Linearity graph of Levocetirizine dihydrochloride

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/170d0a80-30f9-44b8-b067-80f142ec8632/image/d4aa6f3b-c6de-49f3-a592-ec08a7516020-uimage.png

Preparation of working solution

Preparing 0.1 M HCl Solution

Add Conc 2.1 ml. Hydrochloric acid in 250 ml volumetric flask, adjust the volume with distilled water to make 0.1 M HCl solution.

Preparing 0.1 M NaOH Solution

Weight and transfer 1.0 gm of NaOH in 250 ml of Volumetric flask, adjust the volume with distilled water to make 0.1 M NaOH solution.

Preparing 0.3% H2O2 Solution

Pipette out 2.5 ml of 30% H2O2 solution and added into 250 ml of volumetric flask, adjust the volume up to the mark with distilled water to make 0.3% H2O2 solution.

Preparing a Levocetirizine Dihydrochloride solution

The tablets of each of the brands have been weighed individually. Each brand of tablets was crushed in a mortar pestle. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed in each 100 ml volumetric flask, all of which were transferred individually. Add 70 ml of diluent, sonicate to dissolved and dilute to volume with diluent to make up the volume up to 100 ml respectively for each sample. Filter the solution with the Whatman filter paper no. 41; pipette out 5 ml and transfer in 50 ml volumetric flask. By using spectrophotometer with a wavelength of 230.60 nm, all samples were determined.

Forced degradation studies

Acid degradation

The tablets of each of the brands have been weighed individually. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) was carefully weighed in each 100 ml volumetric flask, all of which were transferred individually. Add 10 ml of diluent and 10 ml of 0.1 M HCl solution. Place aside at room temperature for 3 hours, then add 10 ml of 0.1 M NaOH solution. Make a volume of 100 ml with a diluent. Filter this solution through the no. 41 Whatman filter paper and then pipette 5 ml in 50 ml volumetric flask. By using a spectrophotometer at 230.60 nm wavelength, all brand absorbance was determined.

Alkali degradation

The tablets of each of the brands have been weighed individually. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed in each 100 ml volumetric flask, all of which were transferred individually. Add 10 ml of diluent and 10 ml of 0.1 M NaOH solution. Place aside at room temperature for 3 hours, then add 10 ml of 0.1 M HCl solution. Make a volume of 100 ml with a diluent. Filter this solution through the 41 Whatman filter paper and then pipette 5 ml in 50 ml volumetric flask. By using a spectrophotometer with a wavelength of 230.60 nm, all brand absorbance was determined.

Oxidation degradation

The tablets of each of the brands have been weighed individually. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed in each 100 ml volumetric flask, all of which were transferred individually. Add 10 ml of diluent and 10 ml of 0.3 % H2O2 solution. Place aside at room temperature for 3 hours. Make a volume of 100 ml with a diluent. Filter this solution through the no. 41 Whatman filter paper and then pipette 5 ml in 50 ml volumetric flask. By using a spectrophotometer with a wavelength of 230.60 nm, all brand absorbance was determined.

Photolytic degradation at 254 nm (UV-light)

The tablets of each of the brands have been weighed individually. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed and transferred to the petri dishes in the U.V light chamber at 254 nm for 3 hours. The tablets of each of the brands were weighed individually. Powdered was given equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed and transferred to the petri dish in the U.V light chamber at 254 nm for 3 hours.

Thermal degradation

The tablets of each of the brands have been weighed individually. Powdered was administered equal to 15 mg of Levocetirizine. Okacet-L (372 mg), LECOPE (480.36 mg), Levocet (387.86 mg), 1-AL (306.90 mg) were carefully weighed in each 100 ml volumetric flask, all of which were transferred individually. Add 10 ml of the diluent and 10 ml of the water. Place in a water bath for 3 hours at a temperature of 80°C, then cooled the flask and add the volume with diluent up to the mark. Filtered through the 41 Whatman filter paper, then pipette 5 ml in 50 ml volumetric flask. By using a spectrophotometer with a wavelength of 230.60 nm, all brand absorbances have been determined.

Table 1

Manufacturing and Expiry date of various brands of Levocetirizine Dihydrochloride 5 mg

S. No Brand Name Mfg. Date Exp. Date
1 Okacet-L March, 2019 February, 2021
2 LECOPE November, 2019 October, 2021
3 Levocet April, 2019 March, 2021
4 1-AL August,2019 July, 2021

Table 2

Absorbance of each brands in different parameters

S. No. Brand Name Avg. Mean Abs. inUntreated cond. Avg. Mean Abs. in Acidic cond. Avg. Mean Abs. in Basic cond. Avg. Mean Abs. in Oxidation cond. Avg. Mean Abs. in Photolytic cond. Avg. Mean Abs. in Thermal Cond.
1 Okacet-L 0.544 0.474 0.507 0.481 0.403 0.502
2 LECOPE 0.487 0.463 0.476 0.473 0.434 0.461
3 Levocet 0.492 0.469 0.480 0.465 0.441 0.477
4 1-AL 0.491 0.447 0.467 0.453 0.421 0.461

Table 3

Acidic degradation of different brands (0.1 M HCl)

S. No. Brand Name % Assay % Degradation
1 Okacet-L 87.10 12.90
2 LECOPE 95.07 04.93
3 Levocet 95.32 04.68
4 1-AL 91.03 08.97

Table 4

Alkali degradation of different brands (0.1 M NaOH)

S. No. Brand Name % Assay % Degradation
1 Okacet-L 93.10 06.90
2 LECOPE 97.74 02.26
3 Levocet 97.56 02.44
4 1-AL 95.11 04.89

Table 5

Oxidation degradation of different brands (0.3% H2O2)

S. No. Brand Name % Assay % Degradation
1 Okacet-L 88.40 11.60
2 LECOPE 97.12 02.88
3 Levocet 94.51 05.49
4 1-AL 92.26 04.74

Table 6

Photolytic degradation of different brands (254 nm UV-light)

S. No. Brand Name % Assay % Degradation
1 Okacet-L 74.00 24.00
2 LECOPE 89.11 10.89
3 Levocet 89.63 10.37
4 1-AL 85.74 14.26

Table 7

Thermal degradation of different brands (Heat liquid at 80°C)

S. No. Brand Name % Assay % Degradation
1 Okacet-L 92.20 07.80
2 LECOPE 94.66 05.34
3 Levocet 96.95 03.05
4 1-AL 93.89 06.11

Results and Discussion

The aim of degradation studies is to obtain shelf-life, investigate improvements to the drug product and suggest its storage conditions, which will apply to all future lots of the drug product tested manufactured and packaged under similar circumstances.13, 14

No literature was found to use U.V spectrophotometer to test compared degradation of the various Levocetirizine dihydrochloride tablet brands. We have therefore tried this research to compare the degree of degradation of Levocetirizine dihydrochloride in four separate brands using Okacet-L 5 mg tablets of Cipla Ltd., LECOPE 5 mg tablets of Mankind Pharma Ltd., Levocet 5 mg tablets of Hetero Healthcare Limited, 1-AL 5 mg tablets of FDC Limited. And active form of Levocetirizine dihydrochloride. Table 2 shows the absorbance variation after different degradation parameters have an effect. In the acidic condition, the % degradation of tablet Okacet-L (12.90) is very high than the tablet Levocet (04.93) Table 3. In basic condition, the % degradation of tablet Okacet-L (06.90) is more than the tablet LECOPE (02.26) Table 4. In oxidation condition, the % degradation of tablet Okacet-L (11.60) is more than the tablet LECOPE (02.88) Table 5. In photolytic condition, the % degradation of tablet Okacet-L (24.00) is very high than the tablet Levocet (10.37) Table 6. In thermal degradation condition, the % degradation of tablet Okacet-L (07.80) is more than the tablet Levocet (03.05) Table 7.

Conclusion

Studies of degradation of different tablet brands containing 5 mg of Levocetirizine dihydrochloride were used to test as per ICH guidelines. In almost all types of stress conditions, levocetirizine dihydrochloride was found to be degraded and in alkaline condition was found to be less degraded. The method was used is accurate, precise, reproducible and economical. It was concluded that the Levocet and LECOPE brands degraded less than the Okacet-L and 1-AL brands in all stress conditions.

Acknowledgement

The authors are very grateful, H. R. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dhule, for the supports of valuable tools and equipment during laboratory work.

Source of Funding

None.

Conflict of Interest

Authors declare no conflict of interest.

References

1 

S Budavari M O'Neil A Smith P Heckelman J Kinneary The Merck Index13thMerck & Company Incorporated, Whitehouse StationNew Jersey2001

2 

S. National Center for Biotechnology Information. PubChem Database2020https://pubchem.ncbi.nlm.nih.gov/substance/329817657

3 

Madihalli Srinivas Raghu Kanakapura Basavaiah Optimized and validated spectrophotometric methods for the determination of levocetirizine in pharmaceuticals based on charge transfer reactionJ Assoc Arab Univ Basic Appl Sci201212133411815-3852Informa UK Limited

4 

P Shende V Shah D Ghodke R Shah S Patil D Chougule Validation of UV Spectrophotometric method for estimation of Levocetirizine Dihydrochloride in bulk and pharmaceutical formulationJ Pharm Res201031023867

5 

F. Estelle R. Simons Keith J. Simons Levocetirizine: Pharmacokinetics and pharmacodynamics in children age 6 to 11 yearsJ Allergy Clin Immunol20051162355610091-6749Elsevier BV

6 

R Hommoss H Elzein S Haidar Determination of Levocetirizine configurational stability in tablets using chiral HPLC methodInt J Pharm Pharm Sci2011321037

7 

Hashem AlAani I Alashkar Development and validation of stability-indicating RP-HPLC method for the analysis of levocetirizine dihydrochloride and fexofenadine hydrochloride in the presence of parabens in liquid dosage formsInt J Pharm Sci Rev Res20132326471

8 

Kiran V. Jadhav Dinesh L. Dhamecha Geet P. Asnani Pranali R. Patil Mrityunjaya B. Patil Stability-indicating stress degradation studies of lafutidine using UV spectrophotometric methodPharm Methods2013412152229-4708EManuscript Services

9 

Komal Patel Komal Dhudasia Amit Patel Jayant Dave Chaganbhai Patel Stress degradation studies on Telmisartan and development of a validated method by UV spectrophotometry in bulk and pharmaceutical dosage formsPharm Methods20112425392229-4708EManuscript Services

10 

H T G Ich Stability testing of new drug substances and products Q1A (R2)Proceedings of the International Conference on Harmonization2003Geneva

11 

M Morita Determination of levocetirizine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: Application to a bioequivalence studyJ Chromatogr B20088621-21329

12 

K Shaikh A Patil A stability-indicating LC method for the simultaneous determination of levocetirizine dihydrochloride and pseudoephedrine sulfate in tablet dosage formsInt J Chem Tech Res20102145461

13 

M Jakaria A Hasanat M Adnan M N U Chy A Y Mousa Comparative degradation study of different brands of Rabeprazole tablet using UV-spectrophotometerAm J Chem Appl201522325

14 

Jakaria Hazrat Ali Areeful Haque Mohammed Abu Sayeed Shoayeb Ahmed In vitroComparative Forced Degradation Study of Different Brands and Active form of Montelukast sodium using UV SpectrophotometerAsian J Pharm Anal201551262231-5667, 2231-5675Diva Enterprises Private Limited



jats-html.xsl


This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.